Quantum Cyber N.V. current report, Q3 FY2023

Business Context and Reporting Period

This Form 6-K filing is submitted by Mainz Biomed N.V. (not Quantum Cyber N.V. as indicated in metadata) for the nine-month period ended September 30, 2023. The report, dated November 16, 2023, serves to make available the Company's Management's Discussion and Analysis (MD&A), unaudited financial statements, and a press release regarding its financial condition and results of operations.

Key Financial Metrics

The provided text is a cover sheet and does not contain specific numerical data. It references attached exhibits (99.1, 99.2, and 99.3) which contain the detailed financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

No material changes or comparative financial data are disclosed within the text of this Form 6-K. The document solely announces the availability of the detailed reports containing such information.

Guidance, Outlook, and Risks

The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the attached exhibits (MD&A and Press Release) referenced in the report.

Investor Verification Checklist

  • Verify the correct registrant name is Mainz Biomed N.V., not Quantum Cyber N.V.
  • Review Exhibit 99.1 for the Management's Discussion and Analysis of financial results.
  • Review Exhibit 99.2 for the unaudited financial statements for the three and nine months ended September 30, 2023.
  • Review Exhibit 99.3 for the press release dated November 16, 2023, for qualitative commentary.
  • Confirm the incorporation by reference into the Company's Registration Statement on Form F-3 (File No. 333-269091).
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.